0001628280-26-009918
SEC filingAMN Healthcare Services, Inc. reported revenue of $2.73 billion for fiscal year 2025, generating a gross profit of $774.1 million. However, the company recorded a net loss of $95.7 million, primarily driven by significant goodwill impairment losses of $109.5 million and long-lived assets impairment losses of $18.3 million, which contributed to an operating loss of $55.5 million. Despite the net loss, the company generated strong operating cash flow of $269.5 million. The balance sheet shows cash, cash equivalents and restricted cash of $137.9 million at year-end, with fixed assets net of $136.4 million and other assets of $282.6 million. The company's financing activities resulted in a net cash outflow of $295.9 million, primarily due to redemption of senior notes of $500.0 million partially offset by proceeds from new senior notes of $400.0 million.
AMN Healthcare Services reported revenue of $2.73 billion for fiscal year 2025, with cost of revenue totaling $1.96 billion, resulting in gross profit of $774.1 million. The company experienced significant challenges with operating expenses of $829.5 million, which included selling, general and administrative expenses of $593.0 million, depreciation and amortization of $147.9 million, goodwill impairment losses of $109.5 million, and long-lived assets impairment losses of $18.3 million. These factors contributed to an operating loss of $55.5 million. After accounting for interest expense of $45.6 million and an income tax benefit of $5.4 million, the company reported a net loss of $95.7 million. Comprehensive income loss was slightly better at $95.4 million due to other comprehensive income of $309,000. The company reported basic and diluted earnings per share of -$2.00, with weighted average common shares outstanding of 38.5 million for both basic and diluted calculations.
The filing provides consolidated revenue figures without segment breakdown. Revenue of $2.73 billion represents the company's total performance across all business activities. No geographic mix or segment-specific revenue drivers are disclosed in the provided data. The revenue figure represents the company's total top-line performance for the fiscal year ending December 31, 2025.
The company achieved a gross margin of 28.4% based on revenue of $2.73 billion and gross profit of $774.1 million. Operating margin was negative at -2.0% due to the operating loss of $55.5 million. The cost structure shows significant impairment charges, with goodwill impairment losses of $109.5 million and long-lived assets impairment losses of $18.3 million representing substantial non-cash charges that impacted profitability. Selling, general and administrative expenses of $593.0 million represented 21.7% of revenue. Depreciation and amortization expenses totaled $147.9 million, exclusive of depreciation included in cost of revenue.
The company generated strong operating cash flow of $269.5 million despite the net loss, with significant adjustments including depreciation and amortization of $156.6 million, goodwill impairment losses of $109.5 million, and share-based compensation of $30.7 million. Investing activities provided net cash of $4.3 million, including proceeds from sale of disposal group of $65.3 million offset by purchase and development of fixed assets of $35.6 million. Financing activities used $295.9 million, primarily due to redemption of senior notes of $500.0 million partially offset by proceeds from new senior notes of $400.0 million. The balance sheet shows cash, cash equivalents and restricted cash of $137.9 million at year-end, with fixed assets net of $136.4 million and other assets of $282.6 million. Current liabilities include accounts payable and accrued expenses of $162.0 million, accrued compensation and benefits of $298.8 million, and other current liabilities of $116.8 million.
The provided data does not include management guidance, strategic priorities, or specific risk factors from the filing. The financial statements show the company's historical performance for fiscal year 2025 without forward-looking statements or projections. The significant impairment charges and net loss position indicate challenges during the period, while the strong operating cash flow generation suggests underlying business operations remained cash-positive.